Wall Street analysts expect that Assembly Biosciences Inc (NASDAQ:ASMB) will report $12.54 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Assembly Biosciences’ earnings, with the lowest sales estimate coming in at $4.00 million and the highest estimate coming in at $36.04 million. Assembly Biosciences reported sales of $3.08 million during the same quarter last year, which indicates a positive year-over-year growth rate of 307.1%. The business is scheduled to issue its next quarterly earnings report on Monday, August 3rd.
On average, analysts expect that Assembly Biosciences will report full year sales of $20.36 million for the current fiscal year, with estimates ranging from $10.21 million to $40.12 million. For the next financial year, analysts forecast that the company will post sales of $15.80 million, with estimates ranging from $14.00 million to $17.60 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Assembly Biosciences.
Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.98) by $0.22. The business had revenue of $4.08 million for the quarter, compared to analyst estimates of $3.82 million. Assembly Biosciences had a negative return on equity of 45.43% and a negative net margin of 601.75%.
In other news, EVP Richard James Colonno sold 7,812 shares of the stock in a transaction on Tuesday, March 31st. The stock was sold at an average price of $15.04, for a total value of $117,492.48. Following the transaction, the executive vice president now owns 144,821 shares of the company’s stock, valued at approximately $2,178,107.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 12.42% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. State Street Corp raised its stake in Assembly Biosciences by 18.4% during the 1st quarter. State Street Corp now owns 551,324 shares of the biopharmaceutical company’s stock worth $8,176,000 after buying an additional 85,622 shares during the period. Morgan Stanley raised its stake in Assembly Biosciences by 169.2% during the 1st quarter. Morgan Stanley now owns 160,050 shares of the biopharmaceutical company’s stock worth $2,374,000 after buying an additional 100,586 shares during the period. AQR Capital Management LLC acquired a new stake in shares of Assembly Biosciences in the 1st quarter valued at about $175,000. Two Sigma Advisers LP raised its stake in shares of Assembly Biosciences by 1.6% in the 1st quarter. Two Sigma Advisers LP now owns 71,200 shares of the biopharmaceutical company’s stock valued at $1,056,000 after purchasing an additional 1,100 shares during the period. Finally, Atom Investors LP acquired a new stake in shares of Assembly Biosciences in the 1st quarter valued at about $2,002,000. 88.34% of the stock is currently owned by institutional investors and hedge funds.
NASDAQ ASMB traded up $0.65 during trading hours on Friday, reaching $23.81. 166,900 shares of the company’s stock were exchanged, compared to its average volume of 261,602. The stock has a market cap of $757.85 million, a PE ratio of -6.94 and a beta of 1.26. Assembly Biosciences has a one year low of $8.13 and a one year high of $25.07. The firm has a fifty day moving average of $20.86 and a 200-day moving average of $18.82. The company has a current ratio of 12.14, a quick ratio of 12.14 and a debt-to-equity ratio of 0.03.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Further Reading: What is a Reverse Stock Split?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.